Inadequate Monitoring of Psychotropic Medications
Summary
The facility failed to ensure adequate monitoring of psychotropic medications for four sampled residents who were receiving medications for behavioral or psychiatric indications. The deficiency involved Resident 5, Resident 18, Resident 57, and Resident 109, where the record review, observations, and staff interviews showed that the facility did not consistently document specific target behaviors, monitor those behaviors for effectiveness, or reassess continued need for the medications as ordered. For Resident 5, the record showed diagnoses of schizophrenia and insomnia, and the care plan addressed lithium related to schizoaffective disorder and manic speech with rapid thought process. The physician order dated 1/8/2026 directed lithium carbonate 150 mg in the morning for manic speech and rapid thought process, but the medical record did not contain a physician order for behavior monitoring of those symptoms. During interview, the LVN stated there should always be orders to monitor the indicated behavior of psychotropic medications and that the lack of monitoring placed the resident at risk of unidentified and unaddressed changes in behavior. The DON stated monitoring indicated behaviors was important to identify trends or changes and to support physician reassessment or medication adjustment. For Resident 18, the record showed schizoaffective disorder and severe cognitive impairment. The resident had orders for Ativan 0.5 mg twice daily for anxiety manifested by tearful and irritable behavior, lithium carbonate 300 mg twice daily for manic symptoms, and clozapine 200 mg in the morning and 300 mg at bedtime for psychosis. The DON stated the behavioral indications for these medications were different and required behavior monitoring for their specific indications, but the orders for lithium and clozapine were not specific enough for staff to monitor effectiveness. The DON also stated the monitoring records did not document the frequency of tearful and irritable behavior related to Ativan, and staff were unable to monitor the effectiveness of lithium carbonate and clozapine because the target behaviors were not clearly identified. For Resident 57, the record showed schizoaffective disorder and moderate cognitive impairment. The resident had Ativan orders for anxiety, but the orders did not identify the specific anxious behavior. The monitoring records from July 2025 and from January through May 2026 did not show behavior monitoring for anxiety, a specific anxious behavior, or the resident’s use of Ativan. The DON stated the order was not specific enough for staff to adequately monitor effectiveness, that there was no documentation showing why Ativan was started, and that there was no documentation that the medication’s effectiveness was being monitored. For Resident 109, the record showed schizophrenia and severely impaired cognitive skills for daily decision making. The resident was ordered Remeron 15 mg at bedtime for appetite, but observations on multiple days showed the resident lying in bed with eyes closed and unarousable, and staff stated the resident was usually sleepy and often skipped breakfast. The LVN stated there was no documented assessment of continued need or effectiveness for appetite stimulation, and the DON stated there was no documented evidence that the facility assessed continued need, evaluated effectiveness, monitored for adverse effects, or notified the physician regarding the repeated sleepiness and inability to be aroused.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.